Cargando…

M45. EFFICACY AND SAFETY OF THE ASENAPINE TRANSDERMAL PATCH, HP-3070 (SECUADO©), FOR SCHIZOPHRENIA: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, INPATIENT STUDY

Abstract not included.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session II
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234202/ http://dx.doi.org/10.1093/schbul/sbaa030.357

Ejemplares similares

Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)
por: Suzuki, Katsumi, et al.
Publicado: (2021)

Transdermal Asenapine in Schizophrenia: A Systematic Review
por: Carrithers, Brennan, et al.
Publicado: (2020)

M13. INCREASED SAFETY SEEKING IN PATIENTS WITH SCHIZOPHRENIA AND PARANOID THREAT
por: Gangl, Nicole, et al.
Publicado: (2020)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

M194. THE USE OF NOVEL PSYCHOACTIVE SUBSTANCES IN THE PRODROMAL PHASE OF SCHIZOPHRENIA- A CASE SERIES
por: Vasiliu, Octavian
Publicado: (2020)

M222. SURVEY RESULTS FROM TURKEY: KNOWLEDGE ABOUT SCHIZOPHRENIA, PUBLIC STIGMA AND DISCRIMINATION BECAUSE OF SCHIZOPHRENIA
por: Haldun, Soygur, et al.
Publicado: (2020)

M73. DRIVING ABILITIES IN PATIENTS WITH SCHIZOPHRENIA
por: Pardeller, Silvia, et al.
Publicado: (2020)

M190. USE OF NULL PRONOUNS IN SCHIZOPHRENIA
por: Chaves, Monica, et al.
Publicado: (2020)

M168. CLINICAL-ANATOMICAL PHENOTYPES OF SCHIZOPHRENIA
por: Kirschner, Matthias, et al.
Publicado: (2020)

M109. WEIGHT GAIN AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
Publicado: (2020)

Boosting the In Vivo Transdermal Bioavailability of Asenapine Maleate Using Novel Lavender Oil-Based Lipid Nanocapsules for Management of Schizophrenia
por: El-Tokhy, Fatma Sa’eed, et al.
Publicado: (2023)

M64. ADDRESSING THE ROLE OF TIMING ON COGNITION IN SCHIZOPHRENIA
por: Alústiza, Irene, et al.
Publicado: (2020)

M117. ELUCIDATING ARCHITECTURE OF NEGATIVE SYNDROME IN SCHIZOPHRENIA
por: San Ang, Mei, et al.
Publicado: (2020)

M245. AN RCT PROTOCOL OF HYBRID-ECT FOR SCHIZOPHRENIA
por: Rong, Han
Publicado: (2020)

M198. INVESTIGATIONAL DOPAMINE ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA
Publicado: (2020)

M106. VIRTUAL-REALITY COGNITIVE TRAINING AND ASSESSMENT IN SCHIZOPHRENIA
por: Porffy, Lilla, et al.
Publicado: (2020)

M215. FACTORS ASSOCIATED WITH CLOZAPINE RESPONSE AND RESISTANCE IN SCHIZOPHRENIA
por: Lee, Jimmy, et al.
Publicado: (2020)

M55. STRUCTURAL CHANGES RELEVANT TO MUSICAL DEFICITS IN SCHIZOPHRENIA
por: Sawada, Ken, et al.
Publicado: (2020)

M228. THE EFFECT OF SOCIALIZATION ON ANTICIPATORY AND CONSUMMATORY PLEASURE IN SCHIZOPHRENIA
por: Merchant, Jaisal, et al.
Publicado: (2020)

M56. ASSORTATIVE MATING IN SCHIZOPHRENIA AND BIPOLAR DISORDER: A NATIONWIDE COHORT STUDY EXPLORING THE CHARACTERISTICS OF INDIVIDUALS WHO HAVE CHILDREN BY PARTNERS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
por: Greve, Aja, et al.
Publicado: (2020)

M67. UNDERSTANDING SOCIAL COGNITION IN SCHIZOPHRENIA THROUGH THE LENS OF SCHIZOTYPY
por: Lee, Sara-Ann, et al.
Publicado: (2020)

M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE
por: Drosos, Petros, et al.
Publicado: (2020)

M243. EFFECTIVENESS AND SATISFACTION WITH A SCHIZOPHRENIA RECOVERY DAY PROGRAM
por: Murata, Lisa, et al.
Publicado: (2020)

M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA
por: Lindenmayer, Jean-Pierre, et al.
Publicado: (2020)

M75. INCREASED REPULSION OF VISUAL WORKING MEMORY REPRESENTATIONS IN SCHIZOPHRENIA
Publicado: (2020)

M69. IMPROVING VISUAL ATTENTION TO SOCIAL STIMULI IN INDIVIDUALS WITH SCHIZOPHRENIA
por: Klein, Hans, et al.
Publicado: (2020)

M68. COGNITIVE IMPAIRMENT IN NEVER-TREATED SCHIZOPHRENIA SPECTRUM INDIVIDUALS
por: Solis-Vivanco, Rodolfo, et al.
Publicado: (2020)

M11. ALTERED TRANSCRANIAL MAGNETIC STIMULATION ELECTROENCEPHALOGRAPHIC MARKERS IN SCHIZOPHRENIA
por: Voineskos, Daphne, et al.
Publicado: (2020)

M231. INTERNALIZED STIGMA AS A PREDICTOR OF EMPLOYMENT STATUS IN PATIENTS WITH SCHIZOPHRENIA
por: Yi Sum, Min, et al.
Publicado: (2020)

M237. EMOTIONAL INTELLIGENCE AND QUALITY OF LIFE IN SCHIZOPHRENIA AND BIPOLAR-I-DISORDER
Publicado: (2020)

M3. THEORY OF MIND IN INDIVIDUALS WITH FIRST-EPISODE OF SCHIZOPHRENIA AND CHILDHOOD TRAUMA
por: Fares Otero, Natalia E, et al.
Publicado: (2020)

M234. QUALITY OF LIFE IN SCHIZOPHRENIA: THE IMPACT OF RESIDUAL SYMPTOMS AND INTERNALIZED STIGMA
por: Hofer, Alex, et al.
Publicado: (2020)

M227. AN EXPLORATORY STUDY OF AUTOMATED LINGUISTIC ANALYSIS OF SOCIAL NARRATIVES IN SCHIZOPHRENIA
por: Baxter, Tatiana, et al.
Publicado: (2020)

M178. PROTEOMIC EVIDENCES OF COMPROMISED ENERGY METABOLISM IN THE NEURODEVELOPMENTAL COURSE OF SCHIZOPHRENIA
Publicado: (2020)

M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA
por: Amoretti, Silvia, et al.
Publicado: (2020)

M43. MODEL-BASED ANALYSIS OF EFFECTS OF LURASIDONE ON PROLACTIN IN SCHIZOPHRENIA PATIENTS
Publicado: (2020)

M224. LONGITUDINAL DETERIORATION OF GESTURE PERFORMANCE IN SCHIZOPHRENIA IS UNRELATED TO SYMPTOM TRAJECTORIES
por: Pavlidou, Anastasia, et al.
Publicado: (2020)

M58. EVALUATING WEIGHTINGS OF PREDICTIVE AND POSTDICTIVE PROCESSES IN ABERRANT SENSE OF AGENCY IN SCHIZOPHRENIA
por: Oi, Hiroki, et al.
Publicado: (2020)

M164. RESTING-STATE CEREBRAL BLOOD FLOW IN SCHIZOPHRENIA PATIENTS WITH PSYCHOMOTOR SLOWING
por: Lefebvre, Stephanie, et al.
Publicado: (2020)

M219. OVERESTIMATING FUNCTION – A RISK FACTOR FOR SUBOPTIMAL COMMUNITY AID IN SCHIZOPHRENIA
por: Pontén, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dkmtmtpbc9icmt7saiuk06du10